|
For
immediate release
|
19 September 2024
|
|
|
|
ANGLE plc ("the
Company")
AGREEMENT WITH RECURSION
PHARMACEUTICALS
New pharma agreement for
Parsortix CTC analysis
ANGLE plc (AIM:AGL OTCQX:ANPCY), a
world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development
and clinical oncology, is pleased to
announce that it has signed an agreement with Recursion
Pharmaceuticals, Inc. ("Recursion"), a leading clinical stage
TechBio company decoding biology to radically improve
lives.
The agreement is being initiated
with a fully funded pilot study. Further details of the
agreement are confidential between the parties.
ANGLE Chief Executive, Andrew Newland,
commented:
"Whilst the study is modest in size
during the pilot phase, there is the potential for larger follow-on
contracts in the event of a successful pilot study. Recursion has
partnerships with multiple leading large pharma companies and this
agreement, ANGLE's fourth for 2024, further builds on the expansion
of our large pharma services business."
For
further information:
|
ANGLE plc
|
+44
(0) 1483 343434
|
|
Andrew Newland, Chief
Executive
Ian Griffiths, Finance
Director
|
|
|
Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser
|
+44
(0) 20 3207 7800
|
|
FTI
Consulting
Simon Conway, Ciara
Martin
Matthew Ventimiglia (US)
|
+44
(0) 203 727 1000
+1
(212) 850 5624
|
For Frequently Used Terms, please
see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid
biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting
technology known as the Parsortix® PC1 System enables
complete downstream analysis of the sample including whole cell
imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.
ANGLE's commercial businesses are
focusing on diagnostic products and clinical services. Diagnostic
products include the Parsortix® system, associated
consumables and assays. The clinical services business is offered
through ANGLE's GCLP-compliant laboratories. Services include
custom made assay development and clinical trial testing for
pharma.
Over 90 peer-reviewed publications
have demonstrated the performance of the Parsortix system. For more
information, visit www.angleplc.com